Search results

  1. E

    Preprint Management of Nutritional Failure in People with Severe ME/CFS: Review of the Case for Supplementing NICE Guideline NG206, 2024, Edwards (Qeios)

    Whilst I understand the sentiment of the response I fear the focus on “growing body of scientific and clinical evidence explaining the underlying pathology in patients with Severe ME.” makes the response a bit harder to read. After all the papers, such at the paper by Arron et which they cite to...
  2. E

    Speculations about the genetics of ME/CFS and DecodeME

    Is the term "adrenaline" not simply being used because patients think that is what it may feel like, not because adrenaline actually bares any relevance? I think at those times it better to avoid medical terminology, even though most of us might know what is being referred to and maybe we...
  3. E

    USA: Mount Sinai PACS clinic and Dr David Putrino

    You didn't address me, but since I stated I was "worried" let me clarify why. I don't think so and I also think more work on this front is very much warranted. However, is anybody really "digging into it" as you state? I only see people with a shovel in their hand pointing at how many people...
  4. E

    Blood Neurofilament Light Chain: The Neurologist’s Troponin?, 2020, Thebault et al

    It's the Ascherio paper discussed here. I don't think that diagnosis of early MS has in any way changed even with NfL tests being available.
  5. E

    Grip test results and brain imaging in the NIH study: Deep phenotyping of PI-ME/CFS, 2024, Walitt et al

    I have completely forgotten what this was all about and can't wrap my head around it, but from what I can remember @Janna Moen PhD I see this similar as @Hutan. The graph is the graph of the slope of the Dimitrov index. I don't think that they argue that "ME/CFS group could not have muscle...
  6. E

    Plasma Neurofilament Light Chain: A Potential Biomarker for Neurological Dysfunction in ME/CFS, 2024, Azcue et al

    So I quickly looked at the intramural study again and the GFAP levels of pwME are somewhat elevated compared to healthy controls. The results are not statistically significant but that may be another issue. In fact @SNT Gatchaman had already discussed this problem with GFAP in the intramural...
  7. E

    Plasma Neurofilament Light Chain: A Potential Biomarker for Neurological Dysfunction in ME/CFS, 2024, Azcue et al

    Not the first time NFL is appearing. Here is a link to a thread which includes links to several studies in LC and ME/CFS that find abnormalities in NFL. GFAP was also abnormal in the study by den Dunnen. I think we might now really need to have a large and well conducted study on this topic in...
  8. E

    AI-driven multi-omics modeling of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome, 2025, Xiong et al.

    At the same time you should not forget the state of scientific publishing in the AI field. A large majority of junk is churned out on a daily basis, methodologically often no different to the BPS stuff, where mathematical proofs, sometimes even erroneous, are quite often degraded to the...
  9. E

    USA: Mount Sinai PACS clinic and Dr David Putrino

    A long Twitter thread by David Putrino, with some possibly valuable points but also many very worrying points not based on current evidence with statements such as "we know that many people with #LongCOVID and chronic #lyme are sick because of persistent pathogens", "Similarly, for those with...
  10. E

    Are there any evidence-based guidelines on pacing upright activity for orthostatic intolerance?

    This is the first time I hear of this. Was this possibly related to the Fedorowski paper that cited PACE to recommend GET in LC patients and which was reviewed by people at Dysautonomia international? I don't know if there are major issues, but they seem to have always prioritised POTS over PEM...
  11. E

    Use of EEfRT in the NIH study: Deep phenotyping of PI-ME/CFS, 2024, Walitt et al

    Below are some graphs from earlier posts. @Murph and @ME/CFS Skeptic also made some graphs, I also posted some other graphs elsewhere, so did some others, it was all somewhat earlier in this thread.
  12. E

    Long Covid drug BC-007 research news

    That would be possible. But the again Efgartigimod trial was targeted at POTS and the BC007 didn't really look at any subtypes of LC, for instance neurological LC, or anything of that sort and the sample size wasn't too massive to really untangle any subtypes. We'll definitely have to wait for...
  13. E

    Long Covid drug BC-007 research news

    Supposedly this means they have some positive preliminary results, whatever that may actually mean, as I really don't see how it could be able to show a use given the failures of Rituximab and Efgartigimod and all studies finding no relevance of these aabs.
  14. E

    studies that do NOT find a connection between ME and pre existing mental health conditions

    There's also a lot of LC papers showing no connection between LC and pre existing mental health conditions. The possibly most famous LC paper by Iwasaki et al finds
  15. E

    MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence ... Viral Reactivation in Long-COVID, 2024, Haddad+

    Actually having a closer look this is slightly weird. There always seems to be an increase before vaccination and infection. That would not be problematic if there was some steady state around which the levels roughly hover, sometimes being higher sometimes being lower or if it has to do with...
  16. E

    MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence ... Viral Reactivation in Long-COVID, 2024, Haddad+

    Looking at figure 3, which unfortunately is only data for 1 patient, it seems that for repeated vaccinations the MENSA antibody levels are less high after subsequent vaccinations than after initial vaccinations and something similar seems to be the case for repeated infections, where the levels...
  17. E

    MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence ... Viral Reactivation in Long-COVID, 2024, Haddad+

    This is also my major concern. The authors claim to be able to differentiate historic infections from chronic infections, but there is no effort to differentiate recent acute reinfections, which are extremely common and are likely to be biased towards LC patients. This is a particular concern...
  18. E

    MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence ... Viral Reactivation in Long-COVID, 2024, Haddad+

    What is different for HSV2, in their claims that antibodies from circulating plasmablasts indicate recent or current infections?
  19. E

    MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence ... Viral Reactivation in Long-COVID, 2024, Haddad+

    The authors claim that this test capture antibodies secreted from plasmablasts or newly-minted antibody secreted cells that appear in the circulation right after infection or vaccination. I have no idea how this selectively only selects antibodies of these cells and whether this would include...
  20. E

    Zeta Potential as a Diagnostic Tool to Determine the Angina Risk, 2019, Gaikwad et al

    Found this paper when looking for zeta potential which seems to be a key aspect in the paper characterising the electrophysiological-properties of cells in health and disease on me cfs as well as the nanoneedle paper by Davis.
Back
Top Bottom